下一代心力衰竭药物治疗中的生物活性信号通路:综述
本综述探讨了沙库巴曲/缬沙坦(ARNI)通过抑制脑啡肽酶(NEPi)增强生物活性信号通路,并联合血管紧张素II受体阻断(ARB)对射血分数降低的心力衰竭(HFrEF)产生协同有益效应。PARADIGM-HF试验已证实该单分子药物较ACE抑制剂改善HFrEF临床结局,综述进一步识别了可能被增强的信号通路及新型候选分子,提示心力衰竭药物治疗可超越受体拮抗策略。
要点
- 沙库巴曲/缬沙坦通过NEPi增强生物活性信号通路,并联合ARB协同改善HFrEF结局。
- PARADIGM-HF显示该药较ACE抑制剂改善HFrEF临床结局。
- 激活特定受体通路可产生RAS抑制 alone 无法达到的心血管获益。
核心结论
- 激活而非抑制特定受体通路可产生RAS抑制 alone 无法达到的心血管获益,HF药物治疗将超越受体拮抗策略。
研究设计与样本
- 综述,基于PARADIGM-HF等研究,分析NEPi增强的生物活性信号通路及ARB的潜在叠加/协同效应。
主要发现
- PARADIGM-HF中沙库巴曲/缬沙坦较ACE抑制剂改善HFrEF临床结局。
- 综述识别了可能被沙库巴曲/缬沙坦增强的多个生物信号通路及新型候选分子。
临床怎么用
- HFrEF治疗可考虑沙库巴曲/缬沙坦,其通过NEPi和ARB协同作用改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The standard pharmacotherapy for heart failure (HF), particularly HF with reduced ejection fraction (HFrEF), is primarily through the use of receptor antagonists, notably inhibition of the renin-angiotensin system by either angiotensin-converting enzyme inhibition or angiotensin II receptor blockade (ARB). However, the completed Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial identified that the use of a single molecule (sacubitril/valsartan), which is an ARB and the neutral endopeptidase inhibitor (NEPi) neprilysin, yielded improved clinical outcomes in HFrEF compared with angiotensin-converting enzyme inhibition alone. OBSERVATIONS: This review examined specific bioactive signaling pathways that would be potentiated by NEPi and how these would affect key cardiovascular processes relevant to HFrEF. It also addressed potential additive/synergistic effects of ARB. A number of biological signaling pathways that may be potentiated by sacubitril/valsartan were identified, including some novel candidate molecules, which will act in a synergistic manner to favorably alter the natural history of HFrEF. CONCLUSIONS AND RELEVANCE: This review identified that activation rather than inhibition of specific receptor pathways provided favorable cardiovascular effects that cannot be achieved by renin-angiotensin system inhibition alone. Thus, an entirely new avenue of translational and clinical research lies ahead in which HF pharmacotherapies will move beyond receptor antagonist strategies.
引用
- Oatmen KE, Zile MR, Burnett JC, et al. Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA Cardiol. 2018. PMID: 30484834. doi:10.1001/jamacardio.2018.3789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。